Soleno Therapeutics, Inc. (SLNO)

NASDAQ: SLNO · IEX Real-Time Price · USD
0.163
-0.004 (-2.11%)
May 27, 2022 11:39 AM EDT - Market open
Market Cap19.97M
Revenue (ttm)n/a
Net Income (ttm)-27.68M
Shares Out122.84M
EPS (ttm)-0.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume294,051
Open0.170
Previous Close0.166
Day's Range0.160 - 0.171
52-Week Range0.130 - 1.670
Beta0.41
AnalystsBuy
Price Target5.10 (+3,036.5%)
Earnings DateMay 11, 2022

About SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and...

IndustryBiotechnology
IPO DateNov 13, 2014
CEOAnish Bhatnagar
Employees20
Stock ExchangeNASDAQ
Ticker SymbolSLNO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SLNO stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 3,036.53% from the latest price.

Price Target
$5.1
(3,036.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 week ago - GlobeNewsWire

Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 week ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

2 weeks ago - GlobeNewsWire

Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR fo...

Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients

3 weeks ago - GlobeNewsWire

Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering

REDWOOD CITY, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 month ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 month ago - GlobeNewsWire

Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 month ago - GlobeNewsWire

Soleno Therapeutics Announces Proposed Underwritten Public Offering

REDWOOD CITY, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 month ago - GlobeNewsWire

Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome

REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

2 months ago - GlobeNewsWire

Soleno Therapeutics to Participate in the BIO CEO & Investor Conference

REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

3 months ago - GlobeNewsWire

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of r...

3 months ago - GlobeNewsWire

Soleno Concludes Type C Meeting With FDA For Diazoxide Choline In Prader-Willi Syndrome

Soleno Therapeutics Inc (NASDAQ: SLNO) said that on January 20, 2022, the Company received official meeting minutes from the Type C meeting with the FDA's Division of Psychiatry.  The purpose of the mee...

4 months ago - Benzinga

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...

4 months ago - GlobeNewsWire

Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event

REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

4 months ago - GlobeNewsWire

Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround

Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys...

6 months ago - Zacks Investment Research

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of r...

6 months ago - GlobeNewsWire

Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

8 months ago - GlobeNewsWire

Soleno Therapeutics' DCCR Shows Benefit On Hunger, Behavioral Parameters

Soleno Therapeutics Inc (NASDAQ: SLNO) has announced top-line results from its ongoing open-label extension study evaluating DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (...

8 months ago - Benzinga

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

9 months ago - GlobeNewsWire

Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease

The FDA has granted Orphan Drug Designation to Soleno Therapeutics Inc (NASDAQ: SLNO) DCCR (diazoxide choline) Extended-Release tablets for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or...

11 months ago - Benzinga

Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on ...

European Key Opinion Leaders to Participate in Event European Key Opinion Leaders to Participate in Event

1 year ago - GlobeNewsWire

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...

1 year ago - GlobeNewsWire

Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

1 year ago - GlobeNewsWire

Soleno Therapeutics (SLNO) Enters Oversold Territory

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment o...

1 year ago - GlobeNewsWire